REG - Science in Sport PLC - Director/PDMR Shareholding

Science in SportAnnouncement

05/01/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240105:nRSE7211Ya&default-theme=true

RNS Number : 7211Y  Science in Sport PLC  05 January 2024

 

Science in Sport plc

(the "Company")

 

Director/PDMR Shareholding

 

Science in Sport plc (AIM: SIS) has been notified that Gomrath Limited, a
family investment company controlled by Dan Wright, Executive Chairman,
purchased a total of 1,000,000 ordinary shares in the Company on 2 January
2024 at an average price of 11 pence per ordinary share. Following the
transaction, Gomrath Limited are interested in an aggregate of 1,000,000
ordinary shares representing 0.55% of the Company's issued ordinary share
capital.

Additionally, the Company has also been notified that Lombard Odier Asset
Management (Europe) Limited ("Lombard Odier"), PCA of Henry Turcan,
Non-Executive Director of the Company purchased a total of 3,728,485 ordinary
shares in the Company on 2 January 2024 at an average price of 11 pence per
ordinary share. Lombard Odier purchased a further total of 6,017,861 ordinary
shares in the Company on 3 January 2024 at an average price of 11 pence per
ordinary share. Following the transactions, Lombard Odier are interested in an
aggregate of 46,938,024 ordinary shares representing 25.75% of the Company's
issued ordinary share capital.

The notification below is made in accordance with the requirements of the EU
Market Abuse Regulation.

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them:

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Gomrath Limited

 2    Reason for the notification

 a)   Position/status                                              PCA of Dan Wright, Executive Chairman

 b)   Initial notification /Amendment                              Initial Notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Science in Sport plc

 b)   LEI                                                           213800FWYWBJFJPPJ981

 4    Details of the transaction(s): section to be repeated for (i) each type of
      instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument  Ordinary Shares of 10 pence each

      Identification code                                          ISIN: GB00BBPV5329
 b)   Nature of the transaction                                    Purchase of new Ordinary Shares

 c)   Price(s) and volume(s)

 Price(s)  Volume(s)
                                                                    11 pence  1,000,000

 
 d)   Aggregated information

                                                                   Single transaction as in 4 c) above

      Aggregated volume Price
 e)   Date of the transaction                                      2 January 2024

 f)   Place of the transaction                                     XLON

 

d)

Aggregated information

 

Aggregated volume Price

 

Single transaction as in 4 c) above

 

e)

 

Date of the transaction

2 January 2024

 

f)

 

Place of the transaction

 

XLON

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Lombard Odier Asset Management (Europe) Limited

 2    Reason for the notification

 a)   Position/status                                              PCA of Henry Turcan, Non-Executive Director

 b)   Initial notification /Amendment                              Initial Notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Science in Sport plc

 b)   LEI                                                           213800FWYWBJFJPPJ981

 4    Details of the transaction(s): section to be repeated for (i) each type of
      instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument  Ordinary Shares of 10 pence each

      Identification code                                          ISIN: GB00BBPV5329
 b)   Nature of the transaction                                    Purchase of new Ordinary Shares

 c)   Price(s) and volume(s)

  Price(s)  Volume(s)
                                                                   1)  11 pence  3,728,485
                                                                   2)  11 pence  6,017,861

 
 d)   Aggregated information

                                                                   Single transactions as in 4 c) above

      Aggregated volume Price
 e)   Date of the transaction                                      1)   2 January 2024

                                                                   2)   3 January 2024

 f)   Place of the transaction                                     XLON

 

d)

Aggregated information

 

Aggregated volume Price

 

Single transactions as in 4 c) above

 

e)

 

Date of the transaction

1)   2 January 2024

2)   3 January 2024

 

f)

 

Place of the transaction

 

XLON

 

For further information:

 Science in Sport plc                     T: 020 7400 3700
 Dan Wright, Executive Chairman

 Daniel Lampard, CFO

 Liberum (Nominated Adviser and Broker)   T: 020 3100 2000
 Richard Lindley

 John More

 

 Notes to Editors

About Science in Sport plc

Headquartered in London, Science in Sport plc is a leading sports nutrition
business that develops, manufactures, and markets innovative nutrition
products for professional athletes, sports and fitness enthusiasts and the
active lifestyle community. The Company has two highly regarded brands, PhD
Nutrition, a premium active-nutrition brand targeting the active lifestyle
community, and SiS, a leading endurance nutrition brand among elite athletes
and professional sports teams.

 

The two brands sell through the Company's phd.com and scienceinsport.com
digital platforms, third-party online sites, including Amazon and Tmall, and
extensive retail distribution in the UK and internationally, including major
supermarkets, high street chains and specialist sports retailers. This
omnichannel footprint enables the Company to address the full breadth of the
sports nutrition market, sports nutrition market, worth $24.6bn in 2022 and
forecast to grow CAGR 5.9% from 2022 to 2027.(1)

( )

SiS, a leading endurance nutrition business founded in 1992, has a core range
comprising gels, powders and bars

focused on energy, hydration, and recovery. SiS is an official endurance
nutrition supplier to over 320 professional teams, organisations, and national
teams worldwide.

 

SiS is Performance Solutions partner to Ineos Grenadiers cycling team,
Tottenham Hotspur and CGC Nice football, as well as Official Nutrition Partner
to the Milwaukee Bucks, 2021 National Basketball Association Champions.

 

PhD is one of the UK's leading active nutrition brands with a reputation for
high quality and product innovation. The brand has grown rapidly since its
launch in 2005. The range now comprises powders, bars, and supplements,
including the high protein, low sugar range, PhD Smart. PhD brand ambassadors
include leading endurance and strength athlete Ross Edgley and influencer
Gabby Allen.

 

For further information, please visit phd.com and scienceinsport.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHGZGGMLDNGDZM